1. Comparison of total β2-agonist coverage for patients prescribed a) an increased dose of extrafine inhaled corticosteroids (ICS) versus ICS+long-acting β2-agonist (LABA) in separate inhalers or b) fixed-dose combination (FDC) of fine-particle ICS/LABA inhale...
Comparison of total β2-agonist coverage for patients prescribed a) an increased dose of extrafine inhaled corticosteroids (ICS) versus ICS+long-acting β2-agonist (LABA) in separate inhalers or b) fixed-dose combination (FDC) of fine-particle ICS/LABA inhalers versus ICS+LABA in separate inhalers. Data are presented as coverage in hours per 24 h, where the total daily coverage of β2-agonist (short-acting β2-agonist (SABA)+LABA) was calculated as the annual dispensed amount divided by 365 and two puffs of SABA (albuterol 200 μg or terbutaline 500 μg) were defined as lasting 4 h, and two puffs of LABA via pressurised metered-dose inhaler or one puff of LABA via dry powder inhaler were defined as lasting 12 h.
David B. Price et al. ERJ Open Res 2016;2:
©2016 by European Respiratory Society